BR112017002270A2 - aptâmero, uso de um aptâmero, composição farmacêutica, coluna de aférese e método para a preparação de um oligonucleotídeo aptâmero - Google Patents

aptâmero, uso de um aptâmero, composição farmacêutica, coluna de aférese e método para a preparação de um oligonucleotídeo aptâmero

Info

Publication number
BR112017002270A2
BR112017002270A2 BR112017002270A BR112017002270A BR112017002270A2 BR 112017002270 A2 BR112017002270 A2 BR 112017002270A2 BR 112017002270 A BR112017002270 A BR 112017002270A BR 112017002270 A BR112017002270 A BR 112017002270A BR 112017002270 A2 BR112017002270 A2 BR 112017002270A2
Authority
BR
Brazil
Prior art keywords
aptamer
pharmaceutical composition
preparing
oligonucleotide
apheresis column
Prior art date
Application number
BR112017002270A
Other languages
English (en)
Other versions
BR112017002270B1 (pt
Inventor
Müller Johannes
Original Assignee
Berlin Cures Holding Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berlin Cures Holding Ag filed Critical Berlin Cures Holding Ag
Publication of BR112017002270A2 publication Critical patent/BR112017002270A2/pt
Publication of BR112017002270B1 publication Critical patent/BR112017002270B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B99/00—Subject matter not provided for in other groups of this subclass
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)

Abstract

a presente invenção refere-se a novas moléculas de aptâmero para uso no tratamento e/ou diagnóstico de doenças autoimunes associadas com autoanticorpos contra receptores acoplados à proteína g, uma composição farmacêutica que compreende essas moléculas de aptâmero, uma coluna de aférese que compreende essas moléculas de aptâmero e um método para a determinação das sequências de nucleotídeos para uso como sequências de moléculas de aptâmero.
BR112017002270-2A 2014-08-04 2015-08-04 Aptamero, uso de um aptamero, composicao farmaceutica, coluna de aferese e metodo para a preparaqao de um oligonucleotideo aptamero BR112017002270B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14179715.9 2014-08-04
EP14179715.9A EP2982756A1 (en) 2014-08-04 2014-08-04 Aptamers for use against autoantibody-associated diseases
PCT/EP2015/067951 WO2016020377A1 (en) 2014-08-04 2015-08-04 Aptamers for use against autoantibody-associated diseases

Publications (2)

Publication Number Publication Date
BR112017002270A2 true BR112017002270A2 (pt) 2018-01-16
BR112017002270B1 BR112017002270B1 (pt) 2020-11-24

Family

ID=51302898

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017002270-2A BR112017002270B1 (pt) 2014-08-04 2015-08-04 Aptamero, uso de um aptamero, composicao farmaceutica, coluna de aferese e metodo para a preparaqao de um oligonucleotideo aptamero

Country Status (11)

Country Link
US (1) US20170226513A1 (pt)
EP (2) EP2982756A1 (pt)
JP (4) JP6630356B2 (pt)
CN (3) CN117247941A (pt)
AU (1) AU2015299059B2 (pt)
BR (1) BR112017002270B1 (pt)
CA (1) CA2956877C (pt)
DK (1) DK3177723T3 (pt)
ES (1) ES2658492T3 (pt)
PL (1) PL3177723T3 (pt)
WO (1) WO2016020377A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2880291T3 (es) 2011-06-02 2021-11-24 Univ Louisville Res Found Inc Nanopartículas conjugadas a un agente antinucleolina
EP2982756A1 (en) * 2014-08-04 2016-02-10 Berlin Cures Holding AG Aptamers for use against autoantibody-associated diseases
EP3468605A4 (en) 2016-06-08 2020-01-08 President and Fellows of Harvard College MODIFIED VIRAL VECTOR REDUCING THE INDUCTION OF INFLAMMATORY AND IMMUNE RESPONSES
US11981911B2 (en) 2017-11-08 2024-05-14 President And Fellows Of Harvard College Compositions and methods for inhibiting viral vector-induced inflammatory responses
WO2020086895A1 (en) * 2018-10-24 2020-04-30 Scivera LLC Computer-implemented method for quantifying chemical hazard assessment
EP3715375A1 (en) 2019-03-23 2020-09-30 Ablevia biotech GmbH Compound for the prevention or treatment of pre-eclampsia
EP3715374A1 (en) 2019-03-23 2020-09-30 Ablevia biotech GmbH Compound for the sequestration of undesirable antibodies in a patient
EP3715376A1 (en) 2019-03-23 2020-09-30 Ablevia biotech GmbH Compound for the prevention or treatment of myasthenia gravis
US11986536B2 (en) 2019-03-23 2024-05-21 Ablevia Biotech Gmbh Compound for the sequestration of undesirable antibodies in a patient
US20230381334A1 (en) 2020-09-23 2023-11-30 Ablevia Biotech Gmbh Compound for the sequestration of undesirable antibodies in a patient
TW202228784A (zh) 2020-09-23 2022-08-01 奧地利商艾柏力維亞生技有限公司 用以於一患者中螯合非預期的抗ｐｅｇ抗體的化合物
US20230355784A1 (en) 2020-09-23 2023-11-09 Ablevia Biotech Gmbh Compound for the prevention or treatment of autoantibody-mediated conditions
WO2022063892A1 (en) 2020-09-23 2022-03-31 Ablevia Biotech Gmbh Compound for increasing efficacy of viral vectors
JP2023542388A (ja) 2020-09-23 2023-10-06 アブレヴィア バイオテック ゲーエムベーハー 第ｖｉｉｉ因子補充療法の有効性を増加させるための化合物
WO2022063880A1 (en) 2020-09-24 2022-03-31 Ablevia Biotech Gmbh Compound for the prevention or treatment of myasthenia gravis
CN113588937A (zh) * 2021-07-19 2021-11-02 刘艳 一种心肌细胞m3受体的检测方法
CN114533889B (zh) * 2022-02-25 2023-05-26 中南大学 一种DNA功能化PBNPs纳米酶制备方法和在靶向光热治疗剂制备中的应用
WO2023180502A1 (en) 2022-03-24 2023-09-28 Ablevia Biotech Gmbh Compound for increasing efficacy of oncolytic viruses
WO2024038918A1 (ja) * 2022-08-19 2024-02-22 国立大学法人東京農工大学 一本鎖抗体結合アプタマー

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1054892E (pt) * 1998-02-19 2002-12-31 Ortho Mcneil Pharm Inc Peptidomimeticos de azol como antagonistas do receptor de trombina
WO1999065928A2 (en) * 1998-06-19 1999-12-23 Genzyme Corporation Polynucleotide population isolated from non-metastatic and metastatic breast tumor tissues
AU775412B2 (en) * 1999-04-08 2004-07-29 Advanced Cancer Therapeutics, Inc. Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US6740657B2 (en) * 2001-02-23 2004-05-25 Ortho-Mcneil Pharmaceutical, Inc. Aminomethyl-pyrroloquinazoline compounds as thrombin receptor antagonists
WO2005037323A2 (en) 2003-10-10 2005-04-28 University Of Louisville Research Foundation, Inc. Use of gro to treat or prevent inflammation
MEP0208A (xx) 2005-08-26 2010-02-10 Archemix Corp Aptameri koji vezuje trombin sa visokim afininitetom
US20090131351A1 (en) * 2007-11-16 2009-05-21 Antisoma Research Limited Methods, compositions, and kits for modulating tumor cell proliferation
WO2011133142A1 (en) * 2010-04-20 2011-10-27 University Of Louisville Treatment of vhl-negative tumors
EP2402016A1 (en) 2010-06-29 2012-01-04 Charité - Universitätsmedizin Berlin Aptamers that inhibit interaction between antibody and 1st or 2nd extracellular loop of human beta-1-adrenergic receptor
EP2497828A1 (en) 2011-03-07 2012-09-12 Charité - Universitätsmedizin Berlin Use of aptamers in therapy and/or diagnosis of autoimmune diseases
EP2982756A1 (en) * 2014-08-04 2016-02-10 Berlin Cures Holding AG Aptamers for use against autoantibody-associated diseases

Also Published As

Publication number Publication date
PL3177723T3 (pl) 2018-05-30
US20170226513A1 (en) 2017-08-10
EP3177723B1 (en) 2017-12-06
BR112017002270B1 (pt) 2020-11-24
EP2982756A1 (en) 2016-02-10
ES2658492T3 (es) 2018-03-12
CN117247941A (zh) 2023-12-19
CN117230073A (zh) 2023-12-15
JP7267689B2 (ja) 2023-05-02
AU2015299059B2 (en) 2017-08-03
CA2956877A1 (en) 2016-02-11
WO2016020377A1 (en) 2016-02-11
EP3177723A1 (en) 2017-06-14
JP2021035369A (ja) 2021-03-04
JP2018171070A (ja) 2018-11-08
CA2956877C (en) 2019-06-25
JP2017529872A (ja) 2017-10-12
CN106795516A (zh) 2017-05-31
AU2015299059A1 (en) 2017-03-02
JP2023022189A (ja) 2023-02-14
JP6630356B2 (ja) 2020-01-15
DK3177723T3 (en) 2018-02-12

Similar Documents

Publication Publication Date Title
BR112017002270A2 (pt) aptâmero, uso de um aptâmero, composição farmacêutica, coluna de aférese e método para a preparação de um oligonucleotídeo aptâmero
CY1125084T1 (el) Εμβολια νουκλεϊκου οξεος
SV2017005420A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
BR112017025045A2 (pt) plx-8394 ou plx-7904 para uso no tratamento de doenças relacionadas a braf-v600
BR112014014124A2 (pt) Moduladores do receptor de estrogênio fluorados e usos dos mesmos
BR112018003316A2 (pt) compostos e métodos para entrega transmembrana de moléculas
BR112017009497A2 (pt) polinucleotídeos de aadc para o tratamento da doença de parkinson
BR112016007255A2 (pt) polinucleotídeos que codificam receptor de lipoproteína de baixa densidade
DK3294323T3 (da) Adeno-associeret virus til terapeutisk indgivelse til centralnervesystemet
BR112016022553A2 (pt) Compostos e métodos para entrega transmembrana de moléculas?
BR112017008693A2 (pt) célula t modificada, métodos para gerar uma célula t modificada, para tratar uma doença ou condição, para estimular uma resposta imune mediada por célula t e para terapia de transferência de célula adotiva, uso de uma célula t modificada, e, composição.
BR112017012621A2 (pt) peptídeos cíclicos com seletividade de ligação nervosa melhorada, nanopartículas ligadas com os referidos peptídeos cíclicos, e o uso dos mesmos para a produção de imagens de tecido nervoso in vivo em tempo real
BR112016022912A2 (pt) molécula de ligação ao antígeno de imunoativação
BR112014026952A2 (pt) derivados de aminopirimidina pirazol como moduladores lrrk2
BR112016028891A2 (pt) processos de trens de sementes e usos dos mesmos
BR112016014162A2 (pt) uso de um conjugado, conjugado e métodos para a fabricação de um conjugado e para transfectar uma célula
CR20160561A (es) Variantes del anticuerpo anti-factor d y sus usos
BR112016011789A2 (pt) Derivados de purina, composição farmacêutica compreendendo os mesmos e uso dos mesmos
EA201691541A1 (ru) Новые анти-baff антитела
CL2018000597A1 (es) Métodos para tratar enfermedades inflamatorias
BR112016030172A2 (pt) aptâmeros específicos para tlr-4 e usos dos mesmos
BR112014032636A2 (pt) Vacinas atenuadas de streptococcus suis e métodos de produção e usos das mesmas
BR112016020260A8 (pt) uso de um composto na fabricação de um medicamento para tratar uma doença colestática intra-hepática
BR112016019588A2 (pt) produto de ativação de mmp-8, e, método de determinação da ativação da mmp-8 em uma amostra
BR112018012313A2 (pt) composições que compreendem 15-hepe e métodos para uso das mesmas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B25G Requested change of headquarter approved

Owner name: BERLIN CURES HOLDING AG (CH)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/08/2015, OBSERVADAS AS CONDICOES LEGAIS.